Large Molecule Patents
Actemra is a drug owned by Genentech, Inc.. It is protect by 35 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10336983 | GENENTECH, INC. | Method for increasing the specific production rate of eukaryotic cells |
Jul, 2035
(10 years from now) | Active |
| US10017732 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Dec, 2034
(10 years from now) | Active |
| US10676710 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Mar, 2034
(9 years from now) | Active |
| US10829732 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Mar, 2034
(9 years from now) | Active |
| US9630988 | GENENTECH, INC. | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
Jun, 2033
(8 years from now) | Active |
| US10590164 | GENENTECH, INC. | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
Mar, 2033
(8 years from now) | Active |
| US9750752 | GENENTECH, INC. | Subcutaneously administered anti-IL-6 receptor antibody |
Aug, 2032
(7 years from now) | Active |
| US9539263 | GENENTECH, INC. | Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis |
May, 2032
(7 years from now) | Active |
| US10874677 | GENENTECH, INC. | Subcutaneously administered anti-IL-6 receptor antibody |
Mar, 2032
(7 years from now) | Active |
| US10231981 | GENENTECH, INC. | Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis |
Dec, 2031
(6 years from now) | Active |
| US11667720 | GENENTECH, INC. | Subcutaneously administered anti-IL-6 receptor antibody |
Nov, 2031
(6 years from now) | Active |
| US8580264 | GENENTECH, INC. | Subcutaneously administered anti-IL-6 receptor antibody |
Nov, 2031
(6 years from now) | Active |
| US10662237 | GENENTECH, INC. | Method to improve virus filtration capacity |
Aug, 2031
(6 years from now) | Active |
| US8512983 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Jan, 2031
(6 years from now) | Active |
| US10501769 | GENENTECH, INC. | Method for the production of a glycosylated immunoglobulin |
Oct, 2030
(5 years from now) | Active |
| US11021728 | GENENTECH, INC. | Method for the production of a glycosylated immunoglobulin |
Oct, 2030
(5 years from now) | Active |
| US11136610 | GENENTECH, INC. | Method for the production of a glycosylated immunoglobulin |
Oct, 2030
(5 years from now) | Active |
| US11377678 | GENENTECH, INC. | Method for the production of a glycosylated immunoglobulin |
Oct, 2030
(5 years from now) | Active |
| US10982003 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Aug, 2030
(5 years from now) | Active |
| US9714293 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Aug, 2030
(5 years from now) | Active |
| US8568720 | GENENTECH, INC. | High concentration antibody-containing liquid formulation |
Nov, 2029
(4 years from now) | Active |
| US11136375 | GENENTECH, INC. | Method for production of antibody |
Jul, 2029
(4 years from now) | Active |
| US11008394 | GENENTECH, INC. | High concentration antibody-containing liquid formulation |
Dec, 2028
(4 years from now) | Active |
| US11359026 | GENENTECH, INC. | High concentration antibody-containing liquid formulation |
Dec, 2028
(4 years from now) | Active |
| US11584798 | GENENTECH, INC. | High concentration antibody-containing liquid formulation |
Dec, 2028
(4 years from now) | Active |
| US11078294 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) | Active |
| US8574869 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) | Active |
| US8398980 | GENENTECH, INC. | Subtypes of humanized antibody against interleukin-6 receptor |
Feb, 2028
(3 years from now) | Active |
| US8617550 | GENENTECH, INC. | Treatment of vasculitis with IL-6 antagonist |
Mar, 2026
(1 year, 2 months from now) | Active |
| US9902777 | GENENTECH, INC. | Methods for producing subtypes of humanized antibody against interleukin-6 receptor |
May, 2025
(5 months from now) | Active |
| US8734800 | GENENTECH, INC. | Subtypes of humanized antibody against interleukin-6 receptor |
Mar, 2025
(3 months from now) | Active |
| US8709409 | GENENTECH, INC. | Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate |
Jun, 2024
(5 months ago) |
Expired |
| US10744201 | GENENTECH, INC. | Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate |
Apr, 2024
(7 months ago) |
Expired |
| US7521052 | GENENTECH, INC. | Methods for treating interleukin-6 related diseases |
Apr, 2024
(7 months ago) |
Expired |
| US7332289 | GENENTECH, INC. | Method of purifying protein |
Aug, 2023
(1 year, 4 months ago) |
Expired |
Actemra's Family Patents
Explore Our Curated Drug Screens
About Actemra
Active Ingredients:
Approval Date:
Dosage:
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 80MG/4ML (20MG/ML) | Injection | Rx | Intravenous |
| 80MG/4ML (20MG/ML) | Injection | Rx | Intravenous |
| 80MG/4ML (20MG/ML) | Injection | Rx | Intravenous |
| 200MG/10ML (20MG/ML) | Injection | Rx | Intravenous |
| 80MG/4ML (20MG/ML) | Injection | Rx | Intravenous |
| 400MG/20ML (20MG/ML) | Injection | Rx | Intravenous |
| 200MG/10ML (20MG/ML) | Injection | Rx | Intravenous |
| 200MG/10ML (20MG/ML) | Injection | Rx | Intravenous |
| 400MG/20ML (20MG/ML) | Injection | Rx | Intravenous |
| 400MG/20ML (20MG/ML) | Injection | Rx | Intravenous |